Today, KPMG is reporting results from a survey of pharmaceutical executives. In this survey, respondents said they will increase their acquisition activity in the coming year in order to gain…
Luke Timmerman at Xconomy wrote a provocative piece today entitled The Missing Ingredient in Today's Biotech: Guts. His thesis is that the industry is so paralyzed by fear and insecurity that it lacks…
We previously posted our comments on BIO 2011. However, one aspect of the conference that really stood out was the use of social media. Attendees were encouraged to provide links…
The Lacerta Bio team attended the annual BIO Convention in Washington, DC last week. BIO has become one of the key conventions for pharma/biotech business development, and is a "must…
The pharmaceutical industry has benefitted mankind by developing life-saving and life-sustaining drugs. However, recent turmoils have led many to question the value provided by the industry. Matt Herper tackles these complex issues across two blog posts.
The June, 2011 issue of Nature Drug Discovery has a interesting short article based on a survey conducted by our good friends at PharmaVentures. The authors surveyed 180 business development…
We posted in February the news that Pfizer was closing their large R&D facility in Kent, UK. It was with some surprise that we learn that the facility is already…
Bruce Booth from Atlas Ventures has a fascinating story on his blog. We won't steal Bruce's thunder. Instead, we encourage you to read it there first. The gist of the story is…
There is a fascinating discussion taking place over at Derek Lowe's blog today on one-man drug companies: ...some of them are not quite down to one person, but you can…
Today we learn that Rigel has raised $130 million in financing, in part, to develop candidates in rheumatoid arthritis and other areas. But, as reported by Xconomy, the real gem…